Adco-Dol Tablets

    Adco-Dol Tablets

    S2
    PDF Leaflet Revision Date: 28 September 2021


    Clinical Summary

    Quick overview from the medicine insert

    Indication

    Symptomatic relief of mild to moderate pain and fever.

    Dosage (summary)

    1-2 tablets every 4 hours as needed; max 8 tablets/day.

    Special Populations

    • Elderly
    • Renal impairment
    • Hepatic impairment

    Pregnancy & Breastfeeding

    Safety not established in pregnancy and lactation.

    Key Drug Interactions

    • CNS depressants
    • Monoamine oxidase inhibitors
    • Atropine
    • Tricyclic antidepressants

    Contraindications

    • Sensitivity to ingredients
    • Respiratory depression
    • Acute alcoholism
    • Head injuries
    • Bronchial asthma

    Common side effects

    • Sedation
    • Drowsiness
    • Nausea
    • Constipation
    • Dry mouth

    Counselling Points

    • Avoid alcohol
    • Do not exceed recommended dose
    • Consult if no relief in 10 days
    • May cause drowsiness

    Serious warnings

    • Risk of liver damage with overdose
    • Potential for dependency
    • Caution in respiratory conditions
    Important Disclaimer

    The Adco-Dol Tablets professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

    Healthcare Professionals Only

    This content is for registered healthcare professionals

    Sign in or create a free account to read the full package insert.

    Free for HPCSA-registered professionals. Powered by Medinsert.

    Successfully Stashed! 💊

    This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

    View My Favourites
    WhatsApp Email LinkedIn